Arie Belldegrun

Chairman, Allogene; Former CEO
Kite

Dr Arie Belldegrun MD, FACS, is the Executive Chairman and Co-Founder of Allogene. He currently serves as Chairman of Two River Group, UroGen Pharma and Kronos Bio. He is a Co-Founder and Senior Managing Director of Vida Ventures. In 2009, he founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, and served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.